Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 2
1955 1
1957 1
1958 1
1960 2
1961 2
1962 2
1963 3
1964 3
1965 4
1966 5
1967 4
1968 1
1969 2
1970 3
1971 4
1972 6
1973 2
1974 5
1975 2
1976 2
1977 1
1978 4
1979 2
1980 3
1981 4
1983 2
1986 3
1987 5
1988 3
1989 1
1990 1
1991 2
1992 5
1993 7
1994 2
1996 1
1997 4
1998 4
1999 3
2000 1
2002 4
2003 6
2004 5
2005 5
2006 4
2007 1
2008 7
2009 7
2010 2
2011 5
2012 5
2013 9
2014 7
2015 9
2016 9
2017 14
2018 13
2019 25
2020 20
2021 18
2022 16
2023 18
2024 21
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Results by year

Filters applied: . Clear all
Page 1
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
MHC Class II Presentation in Autoimmunity.
Ishina IA, Zakharova MY, Kurbatskaia IN, Mamedov AE, Belogurov AA Jr, Gabibov AG. Ishina IA, et al. Among authors: zakharova my. Cells. 2023 Jan 14;12(2):314. doi: 10.3390/cells12020314. Cells. 2023. PMID: 36672249 Free PMC article. Review.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
[Typical and atypical optic neuritis].
Sheremet NL, Eliseeva DD, Kalashnikova AK, Zakharova MN. Sheremet NL, et al. Among authors: zakharova mn. Vestn Oftalmol. 2023;139(6):175-182. doi: 10.17116/oftalma2023139061175. Vestn Oftalmol. 2023. PMID: 38235645 Review. Russian.
Standardizing designed and emergent quantitative features in microphysiological systems.
Nahon DM, Moerkens R, Aydogmus H, Lendemeijer B, Martínez-Silgado A, Stein JM, Dostanić M, Frimat JP, Gontan C, de Graaf MNS, Hu M, Kasi DG, Koch LS, Le KTT, Lim S, Middelkamp HHT, Mooiweer J, Motreuil-Ragot P, Niggl E, Pleguezuelos-Manzano C, Puschhof J, Revyn N, Rivera-Arbelaez JM, Slager J, Windt LM, Zakharova M, van Meer BJ, Orlova VV, de Vrij FMS, Withoff S, Mastrangeli M, van der Meer AD, Mummery CL. Nahon DM, et al. Among authors: zakharova m. Nat Biomed Eng. 2024 Aug;8(8):941-962. doi: 10.1038/s41551-024-01236-0. Epub 2024 Aug 26. Nat Biomed Eng. 2024. PMID: 39187664 Review.
Multiplexed blood-brain barrier organ-on-chip.
Zakharova M, Palma do Carmo MA, van der Helm MW, Le-The H, de Graaf MNS, Orlova V, van den Berg A, van der Meer AD, Broersen K, Segerink LI. Zakharova M, et al. Lab Chip. 2020 Aug 26;20(17):3132-3143. doi: 10.1039/d0lc00399a. Lab Chip. 2020. PMID: 32756644
[Anti-Ma2 paraneoplastic autoimmune encephalitis].
Chekanova EO, Simaniv TO, Evdokimenko AN, Zakharova MN. Chekanova EO, et al. Among authors: zakharova mn. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):89-95. doi: 10.17116/jnevro202212207289. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 35912563 Russian.
348 results